Nuvectis Pharma (NVCT)
NASDAQ:NVCT
Want to see NVCT full AI Analyst Report?
Top Page
Nuvectis Pharma
(NASDAQ:NVCT)
Select Model
Select Model
Rating:51Neutral
Price Target:
$11.00
▲(23.60% Upside)
Action:Reiterated
Date:06/13/26
The score is held down primarily by weak fundamentals typical of a development-stage biotech (no revenue, widening losses, and notable cash burn), partially offset by a debt-free balance sheet. Technicals are moderately supportive with price above key moving averages and neutral-to-positive momentum, while valuation remains challenged due to negative earnings and no dividend support.
Positive Factors
Debt-free balance sheet
Zero total debt and positive equity (~$14.2M TTM) materially reduce leverage risk and preserve financial flexibility. Over the next 2–6 months this structural strength supports continued R&D spending, potential partner negotiations, and lowers the probability of forced distress financing versus debt-heavy peers.
Negative Factors
Pre-revenue with widening losses
Zero product revenue and materially wider net losses create a structural funding gap: operations are entirely financed externally until commercialization. Over 2–6 months, continued negative profitability constrains reinvestment ability and increases execution risk absent near-term program milestones or financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero total debt and positive equity (~$14.2M TTM) materially reduce leverage risk and preserve financial flexibility. Over the next 2–6 months this structural strength supports continued R&D spending, potential partner negotiations, and lowers the probability of forced distress financing versus debt-heavy peers.
Read all positive factors
Nuvectis Pharma (NVCT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$284.09M
Dividend YieldN/A
Average Volume (3M)89.48K
Price to Earnings (P/E)―
Beta (1Y)2.00
Revenue GrowthN/A
EPS Growth-16.88%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.31
Shares Outstanding26,525,534
10 Day Avg. Volume112,705
30 Day Avg. Volume89,483
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)8.94
Price to Sales (P/S)0.00
P/FCF Ratio-10.29
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.32
Forecast
1Y Price Target
$15.00Price Target Upside68.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.27
Revenue Forecast (FY)N/A
Nuvectis Pharma Business Overview & Revenue Model
Company Description
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound eng...
How the Company Makes Money
As a clinical-stage biotechnology company, Nuvectis Pharma does not have publicly available information indicating recurring revenue from approved product sales. Its funding and cash inflows are therefore primarily associated with capital-raising ...
Nuvectis Pharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -28.06M | -26.44M | -19.00M | -22.26M | -19.09M | -12.89M |
| Net Income | -27.16M | -26.44M | -19.00M | -22.26M | -19.09M | -12.89M |
Balance Sheet | ||||||
| Total Assets | 25.40M | 31.71M | 18.61M | 19.18M | 20.41M | 6.66M |
| Cash, Cash Equivalents and Short-Term Investments | 25.13M | 31.63M | 18.53M | 19.13M | 19.99M | 5.74M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 11.18M | 13.30M | 8.89M | 6.98M | 6.19M | 17.66M |
| Stockholders Equity | 14.22M | 18.41M | 9.71M | 12.20M | 14.22M | -11.01M |
Cash Flow | ||||||
| Free Cash Flow | -18.35M | -16.01M | -12.25M | -15.95M | -13.56M | -9.50M |
| Operating Cash Flow | -18.35M | -16.01M | -12.25M | -15.95M | -13.56M | -9.50M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 13.61M | 29.11M | 11.65M | 15.09M | 27.81M | 15.25M |
Nuvectis Pharma Technical Analysis
Positive
8.90
Price Trends
9.53
Positive
9.05
Positive
7.87
Positive
Market Momentum
0.11
Negative
59.15
Neutral
93.30
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVCT, the sentiment is Positive. The current price of 8.9 is below the 20-day moving average (MA) of 10.12, below the 50-day MA of 9.53, and above the 200-day MA of 7.87, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 59.15 is Neutral, neither overbought nor oversold. The STOCH value of 93.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NVCT.
Nuvectis Pharma Risk Analysis
Nuvectis Pharma disclosed 50 risk factors in its most recent earnings report. Nuvectis Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nuvectis Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $284.09M | -9.23 | -147.78% | ― | ― | -16.88% | |
45 Neutral | $204.62M | -2.13 | -30.90% | ― | ― | 10.70% | |
44 Neutral | $153.96M | -1.96 | -49.86% | ― | -100.00% | 0.03% | |
44 Neutral | $111.51M | -1.37 | -135.60% | ― | ― | 17.43% | |
41 Neutral | $245.51M | -2.88 | -137.99% | ― | 1033.89% | 36.35% |
* Healthcare Sector Average
NVCT
Nuvectis Pharma
10.71
2.07
23.96%
NKTX
Nkarta
2.86
0.97
51.32%
OBIO
Orchestra BioMed Holdings
4.10
0.72
21.30%
GLSI
Greenwich LifeSciences
24.06
14.86
161.52%
MOLN
Molecular Partners
4.11
0.27
7.03%
PYXS
Pyxis Oncology
1.76
0.55
45.45%
Nuvectis Pharma Corporate Events
Executive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Nuvectis Shareholders Approve Director Election and Auditor Ratification
Positive
Jun 12, 2026
On June 11, 2026, Nuvectis Pharma, Inc. held its 2026 Annual Meeting online, later correcting an error in its April 27, 2026 proxy that had overstated the number of common shares outstanding on the April 13, 2026 record date, revising the figure t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.